/
AUTL
$2.22+$0.10 (+4.72%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$564.2M
266M shares
52-week range
$1.18 – $2.43
83% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
ADRC
Change$-3.37
Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
www.autolus.com- Employees
- 752
- IPO / List date
- Jun 22, 2018
- HQ
- LONDON, X0
Held by traders on TradeandTell
No one on the platform currently holds AUTL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,299,499 | $3.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AUTL yet.
